These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29972840)

  • 21. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report.
    Faust AC; Peterson EJ
    J Emerg Med; 2014 Apr; 46(4):525-9. PubMed ID: 24508114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab.
    Braemswig TB; Eschenfelder CC; Nolte CH
    Am J Emerg Med; 2017 Apr; 35(4):662.e3-662.e4. PubMed ID: 27836320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe obscure gastrointestinal bleeding successfully treated with idarucizumab.
    Rodríguez de Santiago E; Sierra Morales M; Martínez González J
    Rev Esp Enferm Dig; 2018 Apr; 110(4):264-265. PubMed ID: 29368938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
    Na SY; Mracsko E; van Ryn J; Veltkamp R
    Ann Neurol; 2015 Jul; 78(1):137-41. PubMed ID: 25899749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
    Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Althaus K; Berrouschot J; Cangür H; Daffertshofer M; Edelbusch S; Gröschel K; Haase CG; Harloff A; Held V; Kauert A; Kraft P; Lenz A; Müllges W; Obermann M; Partowi S; Purrucker J; Ringleb PA; Röther J; Rossi R; Schäfer N; Schneider A; Schuppner R; Seitz RJ; Szabo K; Wruck R
    Int J Stroke; 2017 Jun; 12(4):383-391. PubMed ID: 28494694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.
    Šaňák D; Jakubíček S; Černík D; Herzig R; Kunáš Z; Mikulík R; Ostrý S; Reif M; Rohan V; Tomek A; Veverka T
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2479-2483. PubMed ID: 29807757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
    Comuth WJ; Haase AM; Henriksen LØ; Malczynski J; van de Kerkhof D; Münster AB
    Scand J Clin Lab Invest; 2018; 78(1-2):1-5. PubMed ID: 29148292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
    Sheikh-Taha M
    Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.
    Okishige K; Yamauchi Y; Hanaki Y; Inoue K; Tanaka N; Yamaji H; Murakami T; Manita M; Tabata K; Ooie T; Tatsukawa Y; Sakai H; Yamaki M; Murakami M; Takada T; Osaka Y; Ono Y; Handa K; Sugiyama K; Yoshizawa T; Fukaya H; Tashiro H; Takase S; Harada M; Watanabe E; Yamane T; Yamashita S; Aonuma K
    J Thromb Thrombolysis; 2019 May; 47(4):487-494. PubMed ID: 30955142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
    Crespo-Leiro MG; López-Vilella R; López Granados A; Mirabet-Pérez S; Díez-López C; Barge-Caballero E; Segovia-Cubero J; González-Vilchez F; Rangel-Sousa D; Blasco-Peiró T; de la Fuente-Galán L; Díaz-Molina B; Zatarain-Nicolás E; Carrasco Ávalos F; Almenar-Bonet L
    Clin Transplant; 2019 Dec; 33(12):e13748. PubMed ID: 31670852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome.
    Mazur P; Darocha T; Filip G; Grudzień G; Drwiła R; Kapelak B
    Pol Arch Med Wewn; 2016 Jul; 126(7-8):579-81. PubMed ID: 27452811
    [No Abstract]   [Full Text] [Related]  

  • 36. [The first experience with dabigatran antidote in the University Hospital Pilsen].
    Šlechtová J; Hajšmanová Z; Lavičková A; Šigutová P
    Cas Lek Cesk; 2016; 155(8):442-444. PubMed ID: 28098476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
    Miller L; Ferreira JA; Tucker C
    J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
    Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.